Slashed profit warning over new Indian price regime
This article was originally published in Scrip
Executive Summary
Almost 90 drug products across therapeutic segments could see price cuts of over 30% to as high as 89% under India's new price control order, with industry's current profitability expected to be sliced by almost a fifth, according to early estimates on the impact of the new regulation.